

Liquid Tumor Patient-Derived Xenograft Models

A unique collection of patient-derived
blood cancer models



A JSR Life Sciences Company

QUICKFACT


V1.0

In vivo and ex vivo ALL and AML patient-derived blood cancer models for efficacy testing.

Crown Bioscience's Liquid Tumor PDX are the only validated, stable, truly patient-representative leukemia models commercially available.

- This collection comprises:
 - 19 Acute Lymphoblastic Leukemia (ALL) models
 - 6 Acute Myeloid Leukemia (AML) models
- Well-characterized and annotated models with:
 - Expression profiling (RNAseq and U219) data
 - Gene copy number (WES and SNP6) data
 - MicroRNA data
 - Hotspot mutation analysis available

- Models with patient-relevant mutations e.g., IDH2 mutation, FLT3-ITD(+), BCR/ABL(+)
- Unique models for targeted therapy
- Curated, online, searchable database of phenotypic and genotypic data, patient information, growth curves, and standard of care treatment data



Get in touch



US: +1 858 622 2900
UK: +44 (0)1530 234871

busdev@crownbio.com
www.crownbio.com

